BioAge Labs, Inc. ( (BIOA) ) has released its Q1 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors.
BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company is known for its innovative approach in leveraging human longevity data to address metabolic aging pathways.
In the first quarter of 2025, BioAge Labs reported significant advancements in its pipeline, particularly with its lead candidate BGE-102, an NLRP3 inhibitor for obesity. The company also announced a strategic collaboration with Lilly ExploR&D to expand its therapeutic capabilities and highlighted ongoing progress in its APJ agonist program.
Key financial metrics for the quarter include a net loss of $12.9 million, which is slightly less than the previous year’s loss of $13.0 million. Research and development expenses increased to $11.1 million, driven by IND-enabling activities for BGE-102. General and administrative expenses also rose to $6.8 million, primarily due to increased personnel-related costs.
BioAge Labs remains well-capitalized with $335.1 million in cash and marketable securities, providing a solid financial foundation to support its operations through 2029. The company is poised to continue its strategic focus on developing transformative treatments for metabolic diseases.
Looking ahead, BioAge Labs is optimistic about its future prospects, with expectations of initial clinical data for BGE-102 in the second half of 2025 and continued progress in its strategic collaborations and pipeline development.